93 results about "Allergic contact dermatitis" patented technology

A treatment for urushiol induced contact dermatitis is provided for in a topical treatment. According to the invention, a method is provided for applying a composition of substances to the effected area, working the composition into the effected area, and removing the composition from the effected area. The composition comprises at least one ethoxylate in combination with Sodium Lauryl Sarcosininate (or "SLS"). It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, sodium lauroyl sarconinate, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.

The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg / ppg 18 / 18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents; (2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia; (3) it is a treatment of inflammatory conditions of mucosae; (4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin.

The invention discloses an external preparation for skin. The preparation comprises components including a pseudo-ceramide compound, a steroid, fatty acid and N-acylethanolamine and contains no grease. Through the manner, the preparation can be used for skin care and maintenance as well as treatment of some skin symptoms, particularly dermatitis symptoms such as atopic dermatitis, eczema, acne, seborrhoeic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis and the like, particularly in areas where sebaceous glands are abundant, such as faces, scalp, necks, chests, backs and buttocks.

This invention relates to a remedy for treating allergic contact dermatitis containing a substance having MEK inhibitory action as its effective component.

The present invention relates to compositions and methods for inhibiting metal exposure to tissues.

Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be atopic dermatitis, allergic contact dermatitis, or radiation dermatitis.

Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and / or impaired mood.

It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and / or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. Topical application of APM and / or derivative can reduce or alleviate the symptoms associated with irritation of the skin and / or mucous membranes caused by contact or inhalation of these oils or fumes from burning vegetation containing these oils.

Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata, skin cancers, and related disorders, such as psoriatic arthritis are provided, such methods comprising administering a composition having antigenic and / or adjuvant properties. Compositions which may be usefully employed in the inventive methods include inactivated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells, M. vaccae culture filtrate and compounds present in or derived therefrom, together with combinations of such compositions.

The invention provides a diffractive ring mangiferin in a mango leaf and an application of a mango leaf extract containing the diffractive ring mangiferin in the aspect of antioxidation activity, in particular to an application in preparing a medicine or a cosmetic for preventing or treating symptoms or diseases relevant to an oxygen radical. The symptoms or the diseases relevant to the oxygen radical comprise wrinkles, macula, allergic dermatitis, contact dermatitis or chronic eczema, and the like, and a composition for preventing or treating the symptoms or the diseases relevant to the oxygen radical comprises one or any composition of diffractive ring mangiferin A, diffractive ring mangiferin B or the mango leaf extract with a treating and / or preventing effective dose and an optional pharmaceutical or cosmetic acceptable excipient.

The invention provides a traditional Chinese medicinal composition for treating relapsing allergic dermatitis, wherein fruit of common perilla, peppermint, chrysanthemum and purslane herb are sued as raw medicinal materials and are prepared into orally administrated preparations and externally applied preparations with auxiliary materials according to a conventional process of pharmaceutics. Proved by clinical researches, the medicinal composition has favorable effects of relieving, repairing, allergy resistance, desensitization, skin nourishment and beauty maintain on acute and chronic relapsing allergic dermatitis. Therefore, the medicinal composition can be prepared into various orally administrated preparations and externally applied preparations by adopting the conventional process of the pharmacy of Chinese medicinal herbs; the traditional Chinese medicinal composition can also be used as an active component to produce various skin care products according to the conventional process for producing the skin care products.

A method is provided for diagnosis and induction of immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments, based on knowledge of the role that keratinocytes play in these ailments and is of importance for several conditions, including but not limited to allergic contact dermatitis (ACD), drug hypersensitivity reactions (DHRs) and autoimmune diseases.

Ecto-NTPDase function on Langerhans cells is demonstrated to counteract the nucleotide inflammatory response caused by certain types of chemical irritants. The present invention takes advantage of this observation by, first, providing methods for screening of chemicals for irritant potential based on their ability to induce nucleotide release from keratinocytes. Second, methods are provided for the prevention and treatment of inflammation using NTPDase protein or gene therapy. And third, there also are provided methods for screening candidate compounds for NTPDase modulatory activity, thereby identifying possible pro- and anti-inflammatory agents. Additionally, the role of NTPDases and P2 receptors in hyperactive immune conditions such as autoimmune diseases and allergic reactions such as allergic contact dermatitis has been demonstrated. Therefore, the invention also provides methods for the prevention and treatment of hyperactive immune conditions by using NTPDase inhibitors and / or P2 receptor inhibitors. Further provided are methods for screening candidate compounds for modulatory activity of NTPDase-mediated immune conditions, thereby identifying other possible immunotherapeutic agents.

A traditional Chinese medicine for treating facial contact dermatitis pertains to a traditional Chinese medicine for treating dermatitis and the components include 10g of folium isatidis, 12g of viola yedoensis makino, 12g of erhua, 15g of lightyellow sophora root, 15g of osthol and 15g of belvedere fruit. The auxiliary recipe is: for people with a type I symptom of only erythemas, using a basic recipe; for people with a type II symptom of edema erythemas, papules and blisters, adding 15g of phellodendron and 25g of rhizoma atractylodis; for people with a type III symptom of edema erythemas and blisters accompanied by leakage and erosion, adding 9g of alum. The dosage materials in the prescription are all made from natural Chinese herbal medicines and the Chinese medicine is prepared by a traditional processing method. The materials are easy to be obtained, the recipe and the preparation method are simple and the preparation cost is quite low. Due to simple recipe, natural Chinese herbs in the recipe, convenient use, simple production method, good internal curative effect and low price, the Chinese medicine is particularly suitable for people who live far away from the urban area and in remote villages. For people who have the disease of facial contact dermatitis, the treatment cost is quite low, which solves the curative problem for low-income families, those living in poverty and in places lack of medical conditions.

This invention provides a pharmaceutical composition for topical application to the skin of a patient in need of, comprising neramexane or a pharmaceutically acceptable salt thereof, and at least one gel forming agent for the treatment or prevention of inflammatory skin diseases such as impetigo contagiosa, acne, rosacea, eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, and / or oily skin. The at least one gel forming agent comprises polymers with neutral and / or positively charged polymer backbones.

The invention relates to a desloratadine oral dispersible film which comprises desloratadine, biologically-acceptable water-soluble polymers, plasticizers, purified water and the like, can be dispersed or dissolved quickly in the oral cavity, and is used for treating allergic rhinitis, allergic rhinitis and asthma syndrome, allergic nasal conjunctivitis, allergic dermatitis, allergic asthma and the like. The desloratadine oral dispersible film is free of irritation, convenient to take and carry, fast in effect, good in taste and particularly suitable for being used by the olds and children.

Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata and skin cancers are provided, such methods comprising administering a composition having antigenic and / or adjuvant properties. Compositions which may be usefully employed in the inventive methods include inactivated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells, M. vaccae culture filtrate and compounds present in or derived therefrom, together with combinations of such compositions.

A three dimensional (3-D) model comprising a scaffold and autologous skin cells, the invention also provides methods of predicting immunogenicity and hypersensitivity or allergic or adverse immune reactions to potential therapeutic compounds, biologies, cosmetics and chemical sensitizers using the 3-D model of skin cells. The methods provide an in vitro assay employing autologous blood derived cells in the 3-D skin equivalent model and is of particular utility in the identification and prediction of skin sensitizers and in particular agents that may cause allergic contact dermatitis. The assay of the present invention provides inter alia methods of screening library compounds for sensitizing activity, identifying optimal therapeutics, especially but not exclusively, monoclonal antibodies and kits therefor.

The invention relates to the field of cell model construction, and concretely relates to a method for knocking out a PD-L1 gene in keratinocytes by a CRISPR / Cas9 gene editing method, and a keratinocyte model constructed by the method and an application thereof. The method has the advantages that the PD-L1 knockout keratinocyte stable-transfection strain constructed by the invention can be used not only for the research of psoriasis, but also for the research of other skin diseases with low expression of PD-L1. The construction of the PD-L1 knockout cell strain is helpful for exploring the role of PD-L1 in skin-related diseases such as psoriasis, pityriasis rosea, and allergic contact dermatitis, and further explores the function of PD-L1 in keratinocytes.

The invention relates to a formula of a traditional Chinese medicine used for treating allergic dermatitis. Along with the continuous improvement of the living standards of people, more and more delicacies enter people's recipes, and seafood becomes a common food. However, due to individual differences of different people, a small part of the population suffers from excessive rash and red swelling on the body after eating seafood. Patients suffer from symptoms such as chest tightness and burning sensation on skin surface, which bring great inconvenience for the life of people. The invention provides the formula of the traditional Chinese medicine used for treating allergic dermatitis. The medicine has an excellent treatment effect, and a patient can be cured in a short time.

The invention relates to a medicine for treating allergic dermatitis, which comprises raw material medicines and auxiliary materials, wherein the raw material medicines include 5-9 parts of cortex dictamni, 3-7 parts of cavalerie mosla herb, 1-3 parts of fructus kochiae, 1-5 parts of typhonium giganteum, 8-12 parts of radix sophorae flavescentis, 3-7 parts of rhizoma atractylodis, 2-6 parts of rhizoma paridis, 1-5 parts of panax pseudoginseng, 2-6 parts of pricklyash peel, 3-7 parts of liquorice, 1-3 parts of borneol, 3-7 parts of radix stemonae, 4-8 parts of cortex phellodendri and 6-10 parts of fructus cnidii by weight; and the auxiliary materials include 4-8 parts of potassium hydroxide, 5-9 parts of triethanolamine, 4-8 parts of stearyl alcohol, 1-3 parts of chlorhexidine acetate and 3-7 parts of dexamethasone by weight. Based on the principle combining traditional Chinese and western medicine, the medicine provided by the invention has functions of dispelling wind, arresting itching, clearing heat and removing dampness, contains a little hormone, and realizes quick itching arresting without causing dependence; according to clinical tests, the curative effect is obvious, the average effective rate reaches 95.34%, and the allergic dermatitis does not recur easily; and when in use, the medicine is spread on the wound, is convenient to use and does not avoid certain food.

The invention relates to the field of pruritus resistance, and specifically relates to an application of an anti-TSLP antibody in the preparation of drugs for treating chronic pruritus. The experiment results show that the provided anti-TSLP antibody can prominently relieve the symptoms of chronic pruritus caused by allergic contact dermatitis of mice, and moreover, under an effective treatment dosage, the coordinating ability of movement of mice is not influenced by the anti-TSLP antibody. The anti-TSLP antibody can be taken as the effective component of drugs, can be used to prepare anti-pruritus drugs, can be used to treat chronic pruritus in clinic, especially chronic pruritus caused by allergic contact dermatitis, and does not have a prominent side effect on the coordinating ability of movement.

The invention relates to a medical soap with a supportive therapeutic efficacy to allergic dermatitis. The medical soap adopts a formula as follows in parts by weight: 50 parts of a soap base, 18 parts of glycerinum, 12 parts of sapium discolor, 5 parts of symplocos paniculata, 10 parts of pterocarya stenoptera and 5 parts of acalypha australis. The medical soap provided by the invention has the efficacies of clearing away heat and toxic materials and killing parasites to relieve itching, and also has the supportive therapeutic efficacy to allergic dermatitis.

The invention discloses a Chinese medicinal paste for treating facial contact dermatitis. The traditional Chinese medicine considers that the insufficiency of natural endowment and fur striae and interstitial space looseness are internal factors of pathogenesis of facial contact dermatitis; the skin is externally affected by toxins, then the toxins invade into the skin to compete with qi and blood to result in qi-blood disharmony and stagnant pathogen fever, and then the toxins externally affect the skin to cause the facial contact dermatitis. The Chinese medicinal paste is prepared from the following traditional Chinese medicinal materials including common achyranthes herb, eragrostis poaeoides, Chinese eupatorium root, negundo chastetree leaf, herb of longfruit speedwell, land bone skin, odontites vulgaris moench, linearstripe rabdosia herb, orbicular lindsaea and wild pear root bark, which have the effects of clearing heat and removing pathogenic heat from the blood and toxic material from the body. The Chinese medicinal paste is prepared into a paste in a drug manufacturing room of our hospital, and is externally applied to an affected part, and clinical tests show that the total effective rate of the paste is 97.5% and the curative effect of the paste is very significant.

Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and / or impaired mood.

The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

The invention relates to a traditional Chinese medicinal compound, and particularly relates to a traditional Chinese medicinal composition for treating allergic dermatitis and a preparation method thereof. Problems that a basic curative effect is unreliable and the compliance of a patient is poorer in the prior art are accordingly solved; thus, purposes of being capable of quickly taking effect, having an exact curative effect and being safe can be achieved. The traditional Chinese medicinal composition for treating the allergic dermatitis, which is provided by the invention, is prepared fromthe following bulk drugs in parts by weight: 40 to 65 parts of radix sophorae flavescentis, 15 to 35 parts of fructus cnidii, 20 to 60 parts of fructus kochiae, 30 to 80 parts of rhizoma smilacis glabrae, 3 to 20 parts of herba menthae and 0.1 to 3 parts of radix tripterygii wilfordii. The traditional Chinese medicinal composition is prepared by adopting a specific preparation method.